Carpenter Technology(CRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRS Carpenter Technology

Pre-Mkt 06-08 07:26:26 EDT

483.60

-9.02

-1.83%

盘前485.20

+1.60+0.33%

07:25 EDT

High500.16	Low480.70	Vol614.87K
Open486.29	D1 Closing492.62	Amplitude3.95%
Mkt Cap24.09B	Tradable Cap23.45B	Total Shares49.82M
T/O299.56M	T/O Rate1.27%	Tradable Shares48.50M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRS","market":"US","secType":"STK","nameCN":"Carpenter Technology","latestPrice":483.6,"timestamp":1780689600000,"preClose":492.62,"halted":0,"volume":614869,"hourTrading":{"tag":"盘前","latestPrice":485.2,"preClose":483.6,"latestTime":"07:25 EDT","volume":31,"amount":15029.21013,"timestamp":1780917944118,"change":1.6,"changeRate":0.003309,"amplitude":0.004115},"delay":0,"changeRate":-0.01831025942917458,"floatShares":48497746,"shares":49818822,"eps":9.499019,"marketStatus":"Pre-Mkt","change":-9.02,"latestTime":"06-08 07:26:26 EDT","open":486.29,"high":500.16,"low":480.7,"amount":299563254.4965,"amplitude":0.039503,"askPrice":492.81,"askSize":3,"bidPrice":484.2,"bidSize":10,"shortable":3,"etf":0,"ttmEps":9.499019,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1780925400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":483.6,"dividendRate":0.001654,"preHourTrading":{"tag":"盘前","latestPrice":485.2,"preClose":483.6,"latestTime":"07:25 EDT","volume":31,"amount":15029.21013,"timestamp":1780917944118,"change":1.6,"changeRate":0.003309,"amplitude":0.004115},"postHourTrading":{"tag":"盘后","latestPrice":480,"preClose":483.6,"latestTime":"19:45 EDT","volume":14766,"amount":7140495.11,"timestamp":1780703133900,"change":-3.6,"changeRate":-0.007444,"amplitude":0.010629},"volumeRatio":0.9747775292629681,"impliedVol":0.5188,"impliedVolPercentile":0.716},"requestUrl":"/m/hq/s/CRS/wiki","defaultTab":"wiki","newsList":[{"id":"2641450485","title":"Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2641450485","media":"GlobeNewswire","labels":["policyRegulatory","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641450485?lang=en_us&edition=fundamental","pubTime":"2026-06-08 18:30","pubTimestamp":1780914600,"startTime":"0","endTime":"0","summary":"Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjgren disease and systemic sclerosi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/08/3307910/0/en/Artiva-Biotherapeutics-Highlights-AlloNK-Data-Presented-at-EULAR-2026-FDA-RMAT-Designation-in-Refractory-Rheumatoid-Arthritis-and-Webcast-Today.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRS","BK4588","IE00B7SZL793.SGD","IE0031619046.USD","LU2065731478.USD","LABU","ARTV","BK4139","BK4006","IE00B19Z4B17.USD","IE00B66KJ199.SGD","BK4187","BK4585","RA","LU0963586101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641483061","title":"Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2641483061","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641483061?lang=en_us&edition=fundamental","pubTime":"2026-06-08 18:00","pubTimestamp":1780912800,"startTime":"0","endTime":"0","summary":"Gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% without prophylaxis to 10% with prophylaxisThe maximum tolerated dose has not yet been determinedNo difference is observed in G","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/08/3307886/0/en/Lyell-Immunopharma-Provides-Update-on-Safety-Profile-of-LYL273-in-Relapsed-or-Refractory-Metastatic-Colorectal-Cancer-and-Amends-Phase-1-Trial-to-Phase-1-2-Expansion.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRS","IE00B19Z4B17.USD","BK4585","CAR","LABU","BK4230","LYEL","BK4588","BK4022","GCC","IE0031619046.USD","BK4139","LU0963586101.USD","LU2065731478.USD","IE00B7SZL793.SGD","IE00B66KJ199.SGD","BK4505","BK4187","BK4006","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641290111","title":"Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2641290111","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641290111?lang=en_us&edition=fundamental","pubTime":"2026-06-06 17:15","pubTimestamp":1780737300,"startTime":"0","endTime":"0","summary":"Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 Deep, dose-dependent B ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/06/3307681/0/en/Cullinan-Therapeutics-Presents-Initial-Clinical-Data-for-CLN-978-a-CD19xCD3-T-Cell-Engager-at-the-EULAR-2026-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","BK4187","BK4139","IE0031619046.USD","LU0963586101.USD","IE00B7SZL793.SGD","SLE","CRS","LU2065731478.USD","IE00B19Z4B17.USD","BK4006","IE00B66KJ199.SGD","RA","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640157248","title":"Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640157248","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640157248?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:30","pubTimestamp":1780576200,"startTime":"0","endTime":"0","summary":"FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21 SLE patients now treated, including as outpatient administration in community hospitals Continued d","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/04/3306754/24675/en/Fate-Therapeutics-Showcases-Data-from-FT819-and-FT839-Programs-at-the-European-Congress-of-Rheumatology-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPV","IE00B19Z4B17.USD","BK4077","IE0031619046.USD","FATE","BK4022","BK4006","BK4139","IE00B66KJ199.SGD","SLE","CRS","IE00B7SZL793.SGD","LU0963586101.USD","LU2065731478.USD","BK4230","CAR","BK4187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640181557","title":"Carpenter Technology Director Steven E. Karol disposes of 2,000 common shares worth $975,478.80","url":"https://stock-news.laohu8.com/highlight/detail?id=2640181557","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640181557?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:11","pubTimestamp":1780517467,"startTime":"0","endTime":"0","summary":"Carpenter Technology: Director Steven E. Karol reported a sale of 2,000 common shares on June 1, 2026.Shares sold at an average price of $487.74.Indirect holdings through affiliates stood at 223,381 shares following the sale.Karol also reported direct ownership of 177,000 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carpenter Technology Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL4Ng2Ts:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Carpenter Technology Director Steven E. Karol disposes of 2,000 common shares worth $975,478.80","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0031619046.USD","IE00B19Z4B17.USD","IE00B66KJ199.SGD","IE00B7SZL793.SGD","LU0963586101.USD","CRS","BK4006","LU2065731478.USD","BK4187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640964152","title":"Carpenter Technology director John Anastasio Hart disposes of 250 common shares worth $115,470.33","url":"https://stock-news.laohu8.com/highlight/detail?id=2640964152","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640964152?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:17","pubTimestamp":1780345053,"startTime":"0","endTime":"0","summary":"Carpenter Technology director Anastasios John Hart exercised director stock options for 250 shares at USD 45.12 on May 28, 2026.He sold 250 shares the same day at an average USD 461.88, reducing his direct common stock holding to 0 shares.Hart reported 3,000 director stock options remaining after the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carpenter Technology Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL5TnwQp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Carpenter Technology director John Anastasio Hart disposes of 250 common shares worth $115,470.33","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0031619046.USD","LU2065731478.USD","BK4187","IE00B66KJ199.SGD","CRS","IE00B19Z4B17.USD","LU0963586101.USD","BK4006","IE00B7SZL793.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640570849","title":"Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640570849","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640570849?lang=en_us&edition=fundamental","pubTime":"2026-06-01 22:00","pubTimestamp":1780322400,"startTime":"0","endTime":"0","summary":"LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patientsResponses observed at higher dose levels of LB2102 with an ORR of 28.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304508/0/en/Legend-Biotech-Presents-First-in-Human-LB2102-Results-in-Solid-Tumors-and-New-CARVYKTI-Data-in-Multiple-Myeloma-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PML","LU2065731478.USD","LU1596574779.USD","LU2413665964.HKD","BK4139","BK4201","BK4086","CAR","BK4588","BK4505","IE00B19Z4B17.USD","LU0963586101.USD","BK4022","LU1165135440.EUR","MAS","CRS","IEC","LU1543694498.USD","IE00B7SZL793.SGD","BK4187","IE00B66KJ199.SGD","IE0031619046.USD","BK4585","ORR","LEGN","BK4581","SG9999001440.SGD","LU1721427968.SGD","BK4006","LU0170899867.USD","LU2413666004.HKD","EC","LU1620156130.USD","XBI","LU1620156213.USD","BK4230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640951863","title":"Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640951863","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640951863?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:00","pubTimestamp":1780315200,"startTime":"0","endTime":"0","summary":"One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and metas","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304266/0/en/Immatics-Presents-Clinical-Activity-and-Response-Dynamics-of-Anzu-cel-PRAME-Cell-Therapy-at-2026-ASCO-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0031619046.USD","LU1169590202.USD","CRS","LU1169589451.USD","LU2065731478.USD","IE00B66KJ199.SGD","BK4139","PD","BK4023","IE00B7SZL793.SGD","BK4006","IMTX","IE00B19Z4B17.USD","LU0963586101.USD","BK4187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639048566","title":"Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2639048566","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639048566?lang=en_us&edition=fundamental","pubTime":"2026-05-31 02:30","pubTimestamp":1780165800,"startTime":"0","endTime":"0","summary":"TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease cont","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/30/3303899/0/en/Eikon-Therapeutics-Presents-Data-on-Clinical-Stage-Programs-at-the-2026-Annual-Meeting-of-the-American-Society-of-Clinical-Oncology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRS","BK4187","BK4006","IE00B19Z4B17.USD","IE00B66KJ199.SGD","BK4139","LU0963586101.USD","SSI","AFG","LU2487616109.SGD","LU2065731478.USD","ORR","BK4588","LU0053666078.USD","LU0210528500.USD","BK4117","IE00B7SZL793.SGD","BK4107","IE0031619046.USD","L","EIKN","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639095506","title":"Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2639095506","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639095506?lang=en_us&edition=fundamental","pubTime":"2026-05-30 20:00","pubTimestamp":1780142400,"startTime":"0","endTime":"0","summary":"One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer wi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/30/3303876/0/en/Immatics-Presents-Clinical-Activity-of-IMA203CD8-PRAME-Cell-Therapy-in-Hard-to-Treat-Gynecologic-Cancers-at-2026-ASCO-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B66KJ199.SGD","ORR","BK4139","LU0963586101.USD","LU2065731478.USD","BK4187","BK4006","IE00B7SZL793.SGD","IE0031619046.USD","IE00B19Z4B17.USD","IMTX","CRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638667234","title":"PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2638667234","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638667234?lang=en_us&edition=fundamental","pubTime":"2026-05-28 19:00","pubTimestamp":1779966000,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., May 28, 2026 /PRNewswire/ -- PeproMene Bio, Inc. announced today that updated clinical data from its ongoing Phase 1 study evaluating PMB-CT01, an investigational B-cell activating factor receptor -targeted CAR T-cell therapy, have been selected for an oral presentation at the 2026 Congress of the European Hematology Association .\"When cancer progresses following CD19 CAR T therapy, patients face a significant unmet medical need, with very limited treatment options remaining,\" said Larry W. Kwak, M.D., Ph.D., scientific founder of PeproMene Bio. \"These durable CRs clinically validate BAFF-R as a novel target, while the favorable safety profile observed to date may support future use in outpatient community oncology settings and further exploration in refractory autoimmune diseases.\". PeproMene Bio, Inc. is a clinical-stage biotech company in Irvine, California developing novel therapies to treat cancers and immune disorders. For more information, c","market":"nz","thumbnail":"https://mma.prnewswire.com/media/1972356/Pepromene_Bio_Inc__Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1972356/Pepromene_Bio_Inc__Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/pepromene-bio-announces-oral-presentation-at-eha-2026-highlighting-favorable-safety-and-durable-responses-with-pmb-ct01-baff-r-car-t-cell-therapy-in-b-cell-lymphomas-including-after-prior-cd19-car-t-cell-failure-302783633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","CAR","MRD.AU","IE00B66KJ199.SGD","CR","CRS","BK4161","IE0031619046.USD","IE00B7SZL793.SGD","LU0963586101.USD","BK4022","LU2065731478.USD","BK4230","CRS.AU","IE00B19Z4B17.USD","BK4006","BK4187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131606643","title":"Navigating the Pitfalls of Offshore Trusts as CRS 2.0 Implementation Approaches","url":"https://stock-news.laohu8.com/highlight/detail?id=1131606643","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131606643?lang=en_us&edition=fundamental","pubTime":"2026-05-27 12:51","pubTimestamp":1779857496,"startTime":"0","endTime":"0","summary":"The efficacy of an offshore trust hinges on the consistency between its foundational documents and its ongoing operations, ensuring it can withstand multi-dimensional scrutiny including financial...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZL793.SGD","LU0963586101.USD","BK4006","IE00B19Z4B17.USD","LU2065731478.USD","BK4187","IE00B66KJ199.SGD","CRS","IE0031619046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637328009","title":"Carpenter Technology: This Stock Will Melt Up -- Barron's","url":"https://stock-news.laohu8.com/highlight/detail?id=2637328009","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637328009?lang=en_us&edition=fundamental","pubTime":"2026-05-23 09:30","pubTimestamp":1779499800,"startTime":"0","endTime":"0","summary":"Earnings momentum, pricing power, and high barriers to entry underscore the investment case for the specialty alloys maker. By Todd Chanko. Founded in 1889, the Philadelphia-based company manufactures highly specialized, mission-critical alloys used in aerospace, defense, consumer, medical, and other industrial applications. Its investors presentation cites over 30 disparate product categories, ranging from engines, electric vehicles, weaponry, semiconductors, sporting goods, and orthopedics.Only three companies in the world -- all in the U.S. -- have the capabilities to produce these special alloys, so supply is limited. At the same time, demand for such alloys to build aerospace, defense, medical, and industrial gas turbines is growing. This supply/demand imbalance contributed to another quarter of record operating income for Carpenter. The company's adjusted earnings per share rose by 47% in its latest quarter to a record $2.77 on a 12% jump in sales over the same period, to $812 mi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BA","IE00B66KJ199.SGD","LU0787776722.HKD","BK4187","LU0640476718.USD","IE0031619046.USD","BK4551","BK4516","BOEU","LU0320765646.SGD","LU1162221912.USD","LU1429558221.USD","BK4585","LU0963586101.USD","IE00B775SV38.USD","IE00B3S45H60.SGD","LU1280957306.USD","BK4006","LU1435385759.SGD","RTX","LU2326559502.SGD","EADSY","IE000M9KFDE8.USD","LU1585245621.USD","LU1366192091.USD","RTXG","CRS","LU1929549753.HKD","LU0072461881.USD","IE00B7SZL793.SGD","LU0683600562.USD","LU2065731478.USD","BK4566","LU0162691827.USD","LU1430594728.SGD","BOED","IE00B19Z4B17.USD","BK4588","BOEG","BK4564","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637693613","title":"Analysts’ Top Industrial Goods Picks: Carpenter Technology (CRS), Brambles (BMBLF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637693613","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637693613?lang=en_us&edition=fundamental","pubTime":"2026-05-22 09:10","pubTimestamp":1779412236,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Industrial Goods sector as 2 analysts just weighed in on Carpenter Technology (CRS) and Brambles (BMBLF...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-industrial-goods-picks-carpenter-technology-crs-brambles-bmblf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-industrial-goods-picks-carpenter-technology-crs-brambles-bmblf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0963586101.USD","BK4006","IE00B19Z4B17.USD","BMBLF","CRS","IE00B7SZL793.SGD","LU2065731478.USD","IE0031619046.USD","IE00B66KJ199.SGD","BK4187","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333705","title":"Carpenter Technology: This Stock Will Melt Up -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333705","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637333705?lang=en_us&edition=fundamental","pubTime":"2026-05-21 20:00","pubTimestamp":1779364800,"startTime":"0","endTime":"0","summary":"Dental implants. Cellphones. Golf clubs. Boeing planes. No, these aren't clues frustrating fans of the popular Connections puzzle. They are, nonetheless, connected: Each one began in the heat of Carpenter Technology's high-tech furnaces.Founded in 1889, the Philadelphia-based company manufactures highly specialized, mission-critical alloys used in aerospace, defense, consumer, medical, and other industrial applications. Its investors presentation cites over 30 disparate product categories, ranging from engines, electric vehicles, weaponry, semiconductors, sporting goods, and orthopedics.Only three companies in the world -- all in the U.S. -- have the capabilities to produce these special alloys, so supply is limited. At the same time, demand for such alloys to build aerospace, defense, medical, and industrial gas turbines is growing. This supply/demand imbalance contributed to another quarter of record operating income for Carpenter. The company's adjusted earnings per share rose by 47","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BA","BK4566","LU1435385759.SGD","IE00B775SV38.USD","IE00B3S45H60.SGD","LU1430594728.SGD","LU0787776722.HKD","RTX","LU0072461881.USD","LU1585245621.USD","LU1162221912.USD","CRS","BK4588","BK4585","BOEG","IE00B19Z4B17.USD","BK4550","LU2326559502.SGD","BK4006","IE00B7SZL793.SGD","LU0320765646.SGD","LU0162691827.USD","LU0963586101.USD","BOED","BK4516","LU0640476718.USD","LU1929549753.HKD","LU1429558221.USD","RTXG","LU1366192091.USD","BK4564","BK4187","LU2065731478.USD","IE0031619046.USD","EADSY","IE00B66KJ199.SGD","LU1280957306.USD","LU0683600562.USD","BK4551","BOEU","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636899893","title":"Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2636899893","media":"prnewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636899893?lang=en_us&edition=fundamental","pubTime":"2026-05-20 08:00","pubTimestamp":1779235200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, May 20, 2026 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that Dr. Bing Hou has been appointed Chief Scientific Officer, reporting directly to Dr. Jay Mei, Founder, Chairman, and Chief Executive Officer of Antengene.Dr. Hou's appointment underscores Antengene's commitment to strengthening its innovation-driven R&D model as a global biotech company. In this role, Dr. Hou will lead Antengene's efforts across Drug Discovery, Translational Medicine, and Chemistry, Manufacturing and Controls , with a focus on deepening the Company's research engine and building a pipeline of next-generation therapeutic candidates with transformational potential.\"I am honored and excited to step into the role of Chief Scient","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-appoints-dr-bing-hou-as-chief-scientific-officer-to-lead-innovation-driven-rd-strategy-and-advance-next-generation-pipeline-302776389.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRS","LU0963586101.USD","IE00BHPRN162.USD","LU2237443549.SGD","LU2237443978.SGD","IE00BKVL7J92.USD","BK4006","LU0267386448.USD","LU0170899867.USD","IE00B1BXHZ80.USD","LU0882574139.USD","LU2237443465.HKD","IE0031619046.USD","CMC","LU0149725797.USD","LU2746668461.USD","LU2237443382.USD","BK4080","BK4231","IE00B66KJ199.SGD","LU2065731478.USD","IE00BFXG1179.USD","IND","DBB","LU0971096721.USD","IE00B7SZL793.SGD","BK7095","IE00BZ1G4Q59.USD","CRS.AU","LU2746668974.SGD","ADC","IND.AU","LU2237443895.HKD","ADC.AU","LU2237443622.USD","IE00B19Z4B17.USD","BK4187","LU1363072403.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636701300","title":"J.P. Morgan Remains a Buy on Carpenter Technology (CRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636701300","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636701300?lang=en_us&edition=fundamental","pubTime":"2026-05-19 00:40","pubTimestamp":1779122426,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Bill Peterson maintained a Buy rating on Carpenter Technology yesterday and set a price target of $470.00. Peterson covers the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-buy-on-carpenter-technology-crs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-buy-on-carpenter-technology-crs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0006306889.USD","LU0963586101.USD","LU0053666078.USD","LU1162221912.USD","LU2357305700.SGD","LU1244550221.USD","LU1988902786.USD","LU0210528500.USD","LU1244550577.SGD","LU0158827948.USD","LU0234570918.USD","BK4534","LU0225283273.USD","LU2089283258.USD","BK4006","BK4516","BK4504","LU0106261372.USD","LU1732799900.SGD","LU1791710400.SGD","LU0795875086.SGD","IE00B66KJ199.SGD","BK4127","LU1244550494.USD","BK4585","LU0557290698.USD","LU2089284900.SGD","LU2347655156.SGD","LU1791710582.SGD","LU0098860793.USD","IE00B7SZL793.SGD","LU1064131342.USD","LU1720051017.SGD","LU2028103732.USD","BK4588","CRS","LU0390134368.USD","LU0528227936.USD","LU1989772840.SGD","LU2065731478.USD","LU0267386448.USD","LU0106831901.USD","LU1732800096.USD","LU2487616109.SGD","LU2133065610.SGD","LU0912757837.SGD","IE00B19Z4B17.USD","LU1363072403.SGD","LU0795875169.SGD","LU0320765646.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635772538","title":"Press Release: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635772538","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635772538?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:15","pubTimestamp":1778789700,"startTime":"0","endTime":"0","summary":"Announced Cincinnati Children's Applied Gene and Cell Therapy Center  as Lead Manufacturing Partner. Appointed Andrew Fang, Ph.D., as Head of Business Development. BRISBANE, Calif., May 14, 2026  -- Tempest Therapeutics, Inc.  , a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update.\"We made strong progress in the first quarter as we continued to execute across our lead program TPST-2003,\" said Matt Angel, Ph.D., President and Chief Executive Officer of Tempest. \"We advanced key activities supporting the planned initiation of our U.S. registrational study of TPST-2003 in patients with rrMM, including announcing our lead manufacturing partner AGCTC and taking delivery of the TPST-2003 lentiviral vector, a critical component in the manufacturing of TPST-2003. At the same time, we strengthened our ability to unlock ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B66KJ199.SGD","BK4211","BK4187","BK4006","EMD","BK4195","BK4022","BK4139","CAR","IE00B7SZL793.SGD","IE0031619046.USD","BK4230","LU0963586101.USD","BK4161","LU2065731478.USD","PFS","CR","IE00B19Z4B17.USD","TPST","CRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635719179","title":"Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2635719179","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635719179?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:00","pubTimestamp":1778756400,"startTime":"0","endTime":"0","summary":"AUCATZYL (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UKCompany achieves positive g","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294731/0/en/Autolus-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRS","LU0320765646.SGD","LU0963586101.USD","LU1732799900.SGD","LU1988902786.USD","BK4139","IE00BKVL7J92.USD","LU0528227936.USD","LU0795875169.SGD","LU0267386448.USD","LU0106261372.USD","LU1791710400.SGD","LU1989772923.USD","LU2023251221.USD","LU0985320562.USD","LU1668664300.SGD","BK4516","LU1548497426.USD","BK4534","LU1244550221.USD","IE00B66KJ199.SGD","LU1064131342.USD","LU1074936037.SGD","LU0158827948.USD","LU2065731478.USD","LU2111349929.HKD","LENZ","BK4539","LU0557290698.USD","LU0912757837.SGD","LU1720051108.HKD","BK4007","LU0106831901.USD","LU0158827781.USD","LU0971096721.USD","BK4230","LU2264538146.SGD","IE00B7SZL793.SGD","CAR","IE00BZ1G4Q59.USD","BK4581","LU0098860793.USD","BK4585","LU2355687059.USD","BK4588","LU2089283258.USD","ALL","BK4127","LU1244550577.SGD","LU1720051017.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635719174","title":"Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2635719174","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635719174?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:00","pubTimestamp":1778756400,"startTime":"0","endTime":"0","summary":"A single infusion of the lowest dose of rese-cel administered without preconditioning, after discontinuation of all immunomodulators, demonstrated compelling drug-free responses for 6 months in 2 of 4","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294751/0/en/Cabaletta-Bio-Presents-Preconditioning-free-Clinical-Data-and-Automated-Manufacturing-Translational-Data-for-Rese-cel-at-ASGCT-2026-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","IE00B66KJ199.SGD","BK4209","LU2065731478.USD","LU0963586101.USD","BK4139","PC","CRS","IE0031619046.USD","BK4006","CABA","BK4187","IE00B7SZL793.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.carpentertechnology.com","stockEarnings":[{"period":"1week","weight":0.0312},{"period":"1month","weight":0.0555},{"period":"3month","weight":0.2493},{"period":"6month","weight":0.5746},{"period":"1year","weight":0.9574},{"period":"ytd","weight":0.536}],"compareEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":0.0051},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.0756},{"period":"1year","weight":0.2437},{"period":"ytd","weight":0.0816}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Carpenter Technology Corporation engages in the manufacture, fabrication, and distribution of specialty metals in the United States, Europe, the Asia Pacific, Mexico, Canada, and internationally. It operates in two segments, Specialty Alloys Operations and Performance Engineered Products. The company offers specialty alloys, including titanium alloys, powder metals, stainless steels, alloy steels, and tool steels, as well as additives, and metal powders and parts. It serves aerospace, defense, medical, transportation, energy, industrial, and consumer markets. The company was founded in 1889 and is headquartered in Philadelphia, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.456522,"avgChangeRate":-0.006705},{"month":2,"riseRate":0.652174,"avgChangeRate":0.027439},{"month":3,"riseRate":0.521739,"avgChangeRate":0.000589},{"month":4,"riseRate":0.574468,"avgChangeRate":0.045813},{"month":5,"riseRate":0.553191,"avgChangeRate":0.025887},{"month":6,"riseRate":0.531915,"avgChangeRate":0.000178},{"month":7,"riseRate":0.5,"avgChangeRate":0.022964},{"month":8,"riseRate":0.456522,"avgChangeRate":-0.007895},{"month":9,"riseRate":0.608696,"avgChangeRate":-0.003285},{"month":10,"riseRate":0.347826,"avgChangeRate":-0.015075},{"month":11,"riseRate":0.717391,"avgChangeRate":0.060126},{"month":12,"riseRate":0.608696,"avgChangeRate":0.016172}],"exchange":"NYSE","name":"Carpenter Technology","nameEN":"Carpenter Technology"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Carpenter Technology(CRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Carpenter Technology(CRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Carpenter Technology,CRS,Carpenter Technology股票,Carpenter Technology股票老虎,Carpenter Technology股票老虎国际,Carpenter Technology行情,Carpenter Technology股票行情,Carpenter Technology股价,Carpenter Technology股市,Carpenter Technology股票价格,Carpenter Technology股票交易,Carpenter Technology股票购买,Carpenter Technology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Carpenter Technology(CRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Carpenter Technology(CRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}